A Prospective, Open Label, Randomized, Parallel-group Investigation to Evaluate the Efficacy and Safety of Enoxaparin Versus no Enoxaparin in Subjects With Chest Pain Syndrome and no ECG or Biomarker Abnormalities (IDEAL)

NCT00518245 Phase 4 TERMINATED

The purpose of this study is to determine whether enoxaparin (an anticoagulant) is effective in the treatment of patients presenting to the emergency room with chest pain and no electrocardiogram or bloodwork evidence of a heart attack, but with other high risk clinical features

Details

Lead sponsor	Canadian Heart Research Centre
Phase	Phase 4
Status	TERMINATED
Enrolment	11
Start date	2007-08
Completion	2009-08

Conditions

• Unstable Angina

Interventions

• enoxaparin

Primary outcomes

• The incidence of, and time to, the composite endpoint of death, nonfatal MI, recurrent myocardial ischemia, or need for coronary revascularization — 30 days

Countries

Canada